Background. Hypertension is common among renal transplant recipients (RTR) and a risk factor for graft failure and mortality. Sodium intake is a well-established determinant of blood pressure (BP) in the general population. However, data in RTR are limited. International guidelines recommend a maximum daily sodium intake of 70 mmol. We investigated sodium intake in RTR as compared to healthy controls and its association with BP. Methods. We included 660 RTR (age 53 ± 13 years, 58% male) and 201 healthy controls (age 54 ± 11 years, 46% male). Sodium intake was assessed from 24-h urine collections. The morning after completion of urine collection, BP was measured according to a strict protocol. Results. Urinary sodium excretion was 156 ± 62 mmol/ 24 h in RTR and 195 ± 75 in controls (difference: P < 0.001), and 95% of RTR had a urinary sodium excretion >70 mmol/24 h. Systolic BP (SBP) and diastolic BP (DBP) were 136 ± 18 and 82 ± 11 mmHg, respectively. Sodium intake was positively associated with SBP (β = 0.042 mmHg/mmol/24 h, P = 0.002) and DBP (β = 0.023 mmHg/mmol/24 h, P = 0.007), independent of potential confounders. Conclusions. Although RTR had a lower sodium intake than healthy controls, their intake still exceeded current guidelines. Reduction of sodium intake to recommended amounts could reduce SBP by 4-5 mmHg. Better control of sodium intake may help to prevent graft failure and mortality due to hypertension among RTR.
Introduction
Renal transplantation is the preferred treatment for patients with end-stage renal disease. Short-term graft survival after clinical transplantation has improved progressively over the last decades. However, allograft and patient survival in the long-term have not parallelled this improvement [1] . A leading cause of long-term morbidity and mortality among renal transplant recipients (RTR) is cardiovascular disease (CVD) and therefore, attention should be paid to its prevention and treatment [2, 3] . A major contributor to CVD is hypertension, which is very common after renal transplantation. Epidemiological studies indicate that 50-90% of RTR either have hypertension [defined as blood pressure (BP) >140/90 mmHg] or are on anti-hypertensive medications [4, 5] . Prevention and treatment of hypertension should therefore receive proper attention.
Numerous studies have been performed on identification of factors that are positively associated with hypertension. High salt intake is an established risk factor for hypertension in the general population [6] [7] [8] [9] but also in populations with chronic kidney disease (CKD) [10, 11] . Data on the association between sodium intake and BP in RTR, however, are sparse and inconclusive. The latter may be due to the relatively small sample size of studies [12] [13] [14] or a long time lag between collection of data on sodium intake and measurement of BP [15] .
The Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines on hypertension and anti-hypertensive agents in CKD anticipate a rise in the prevalence of hypertension among adults in the USA [16] . Like the Dietary Approach to Stop Hypertension (DASH) guideline, they advocate moderate consumption of sodium with a maximum daily intake of ∼100 mmol/ day, equalling 5.8 g of sodium chloride/day [17] . Guidelines provided by the US Department of Health and Human Services (HHS) and the US Department of Agriculture (USDA) promote an even stricter regimen of no more than 1500 mg/day (∼70 mmol/day) in individuals with hypertension, the middle-aged and in older adults [18, 19] . A previous study reported that sodium intake in RTR is higher rather than lower than in healthy controls and usually exceeds even the conservative limit of 100 mmol/day [14] .
The aim of our study, therefore, was to compare sodium intake in RTR with that in healthy controls and to investigate the association of dietary sodium intake with BP in a large single-centre RTR cohort study under conditions of routine clinical care.
Materials and methods

Subjects
We invited all adult RTR with a functioning graft for at least 1 year who visited our outpatient clinic between 2008 and 2010. A group consisting of 660 of 702 initially invited RTR signed written informed consent. As a healthy reference group, we included all 201 subjects evaluated for living kidney donation in our centre during the same period. None had a history of kidney disease, diabetes or cardiovascular events. Hypertension, if present, was regulated with a maximum of one anti-hypertensive drug. All participants signed informed consent. The Institutional Review Board approved the study protocol (METc 2008/186), which was in adherence to the Declaration of Helsinki.
Data collection
Height, weight and waist circumference were measured on the day of the visit to the outpatient clinic. Body mass index (BMI) was calculated as weight divided by height squared (kg/m 2 ) and body surface area (BSA) was estimated applying the universally adopted formula of DuBois and DuBois [20] . Information on medication use was derived from patient records and data on smoking behaviour were acquired with a questionnaire. RTR were classified as current smokers, former smokers or never smokers.
Blood was drawn after an 8-12 h overnight fasting period in the morning after completion of the 24-h urine collection. To assure adequate urine collection, both RTR and healthy controls were carefully instructed. Subjects were informed to discard their morning urine specimen, collect all subsequent urine through the next 24 h and include the next morning's first specimen of the day of their visit to the outpatient clinic. Renal function was assessed by 24-h urinary creatinine clearance (mL/min) calculated as time-factored urinary creatinine concentration (mg/min) divided by plasma creatinine concentration (mg/ mL). Daily salt intake was assessed on the basis of 24-h urinary sodium excretion (UNaV), since urinary sodium excretion largely equals sodium intake, when people are in steady state [21, 22] . Adequacy of 24-h collection was assessed by comparing the actual 24-h creatinine excretion rate (CER) with creatinine excretion as predicted by body dimensions, age and gender [23] . In secondary analyses, urine samples deviating >30% from the predicted CER were excluded to investigate the association between UNaV and BP in RTR without possible noise due to inadequate urine collections.
Fasting BP (mmHg) was measured according to a standard protocol, which has been used in clinical studies from our department [24, 25] and in the large epidemiological PREVEND study (n = 8592) [26, 27] . BP was measured with one and the same semi-automatic device (Dinamap® 1846; Critikon, Tampa, FL) and all measurements were performed by the same investigator. To prevent white coat effects [28] , participants were left alone in a room in a half-sitting position while BP and heart rate were measured every minute for 15 min. The average of the last three values was taken as BP value in our study. The validity of this procedure is shown in Figure 1 , depicting mean BP and heart rate over time. Systolic BP (SBP) and diastolic BP (DBP) of the averaged last three measurements were, respectively, 14 and 7 mmHg lower than the first measurement (both P < 0.0001). BP reaches a plateau after about 10 measurements, equivalent to 10 min. The day-to-day coefficient of variation for BP evaluated in this way was 2.0% for SBP and 4.3% for DBP. Mean arterial pressure (MAP) was calculated as twice the DBP plus SBP divided by three, approximating the average arterial pressure during a single cardiac cycle [29] . Measurements were performed while patients were on their regular medication, including anti-hypertensive drugs at trough. All measurements were performed at the morning of the visit to the outpatient clinic.
Statistical analysis
Analyses were performed using SPSS version 16.0 software (SPSS Inc., Chicago, IL). Normality was tested with the Kolmogorov-Smirnov test. Skewed data were normalized by logarithmic transformation in analyses. Parametric variables are expressed as mean ± SD, whereas non-parametric variables are given as median [interquartile range].
Differences between RTR and healthy controls were tested with the ttest for independent samples, the Mann-Whitney U-test or the chisquare test. To visualize associations of UNaV with BP in RTR, this study population was divided into gender-stratified tertiles of MAP. Pvalues for differences between these tertiles were obtained using the analysis of variance, Kruskal-Wallis test or chi-square test. Linear trends of variables over the tertiles of MAP were analysed applying univariate linear regression analysis, to identify potential confounders of the association between sodium intake and BP. The association of sodium intake with MAP, SBP and DBP was investigated with multivariate linear regression analyses, with adjustments for age and gender (Model 1), subsequently for waist circumference, renal function and smoking behaviour (Model 2) and plasma potassium concentration, urinary potassium excretion, proteinuria, HbA1c (continuous) and use of anti-hypertensives (ordinal) and calcineurin inhibitors (dichotomous) (Model 3). A twosided P-value <0.05 was considered to indicate statistical significance.
Results
The characteristics of RTR and healthy controls are shown in Table 1 . The two groups were similar with respect to age, BMI and BSA. Men were over-represented in the RTR group compared to the healthy controls.
Sodium intake, as inferred from 24-h urine sodium excretion, was significantly lower in the RTR group than in the healthy controls (156 ± 62 versus 195 ± 75 mmol/ 24 h, P < 0.0001). Sodium intake in the RTR group ranged from 19 to >300 mmol/day. Of all RTR, 85% had a sodium intake >100 mmol/day and 95% had a sodium intake exceeding 70 mmol/day as recommended in international guidelines. One-fifth of the patients had a sodium intake over 200 mmol/day.
As anticipated, creatinine clearance was significantly lower in RTR than in healthy subjects (65 ± 26 versus 123 ± 37 mL/min, P < 0.0001). BP was significantly higher in RTR than in controls (MAP 107 ± 15 versus 95 ± 17 mmHg, P < 0.001; SBP 136 ± 18 versus 125 ± 15 mmHg, P < 0.0001; DBP 83 ± 11 versus 76 ± 9 mmHg, P < 0.0001), despite significantly more use of anti-hypertensive drugs in RTR, as shown in Table 2 . The majority of RTR (91%) either had hypertension or was on anti-hypertensive medications. Seventy-two (11%) RTR were not using any anti-hypertensive drugs, while 198 (30%) RTR used one, 231 (35%) two and 159 (24%) three or more different anti-hypertensive drugs.
In RTR, MAP was significantly higher in men than in women (108 ± 14 versus 105 ± 16 mmHg, P = 0.02). Therefore, further characteristics are presented according to gender-stratified tertiles of MAP (Table 3) . With increasing BP, RTR were older and had higher BMI and BSA. Smoking behaviour did not differ between tertiles. Regarding use of medication, more RTR were on anti-hypertensive medication in the highest tertile of MAP. Furthermore, use of anti-diabetic drugs and calcineurin inhibitors gradually increased over the tertiles. Plasma creatinine and proteinuria differed significantly between tertiles (both P < 0.001); however, creatinine clearance was similar. UNaV increased along with increasing BP. In the highest tertile, mean UNaV excretion was 165 mmol compared to 152 mmol in the lowest tertile (P < 0.001). Figure 2 shows the mean BP values across gender-stratified tertiles of UNaV. SBP, DBP and MAP were all significantly higher in the highest tertile compared to the lowest tertile of urinary sodium excretion (138 versus 134 mmHg, P = 0.01; 84 versus 81 mmHg, P = 0.003 and 102 versus 98 mmHg, P = 0.005, respectively). Urinary volume increased with increasing tertiles of urinary sodium excretion (2209 ± 734, 2244 ± 749 and 2660 ± 847 mL, respectively, P < 0.001). The same was true for urinary sodium concentrations (48 ± 19, 67 ± 23 and 91 ± 33 mmol/L, respectively, P < 0.001).
Associations between UNaV and BP in RTR, analysed as continuous variables, are shown in Table 4 . With adjustment for age and gender, βs for the association with MAP, SBP and DBP were 0.030 (P < 0.001), 0.038 (P = 0.001) and 0.026 (P < 0.001), respectively. Additional adjustment for confounders, as accounted for in the third model, revealed βs of 0.030 (P = 0.002), 0.042 (P = 0.002) and 0.023 (P = 0.007) for the association of UNaV with MAP, SBP and DBP, respectively.
Adequacy of urine collection
In secondary analyses, reliability and completeness of the 24-h urine collections of RTR were evaluated by comparing 24-h creatinine excretion with estimated creatinine excretion applying the equation recently proposed by Ix et al. Samples deviating >30% were excluded and analyses for the association between UNaV and BP were repeated. Based on all separate expected urinary creatinine clearances, 77% of all urine samples were considered to be collected properly. Consequently, the sample size of our study was reduced noticeably, leaving us with 502 samples. Nevertheless, associations of UNaV with MAP, SBP and DBP became slightly stronger, with βs of 0.033 (P < 0.001), 0.045 (P = 0.001) and 0.026 (P = 0.003), respectively (data not shown).
Discussion
Hypertension is highly prevalent among RTR and contributes to CVD and mortality in these patients [30, 31] . In agreement, in our population, the large majority of RTR had hypertension, defined as a BP >140/90 mmHg or the use of anti-hypertensive medications. Contrary with prior reports [12] [13] [14] [15] , we found that sodium intake in RTR was lower than in control subjects with similar body composition. Nevertheless, in 95% of the patients, sodium intake still exceeded the 70 mmol as recommended in current guidelines. In RTR, a significant association between sodium intake and BP was observed, for both SBP and DBP, independent of potential confounders. As for RTR, it can be inferred that in our population, compliance with the maximally recommend daily intake of 70 mmol would have reduced mean SBP and DBP with ∼5 and 3 mmHg, respectively. This study is the first to demonstrate a positive association between sodium intake and BP in RTR. These data suggest that better control of sodium intake can lead to clinically relevant improvement of BP in RTR.
The finding that RTR consume less sodium than the controls (despite similar age and body composition) may be due to the fact that they were under medical supervision, including regular attention for general lifestyle advice. As for RTR, the large majority of patients have been under close dietary supervision during the period of end-stage renal disease preceding renal transplantation. The lower potassium excretion suggests that the dietary habits of the RTR still partly reflect the dietary restrictions during dialysis. Nevertheless, mean daily sodium intake in RTR still exceeded current international guidelines, as was also found in several previous studies reporting mean 24-h urinary sodium excretion rates of 178, 163, 224 and 165 mmol/24 h, respectively [12] [13] [14] [15] . This clearly leaves room for improvement.
Considering the achievement of sodium restriction goals, RTR performed comparably as patients with CKD, in whom sodium intake is generally more or less equal to the general population, as reviewed elsewhere [32, 33] .
We acknowledge that this study has limitations. Firstly, it is a cross-sectional epidemiological study. Therefore, no causal relationship can be proven. Subjects with a high sodium intake for instance may have other dietary or lifestyle habits than subjects with a lower sodium intake which might influence BP. The observation that the association remains significant in the multivariate regression analysis indicated that it is independent of the tested potential confounders, including age, gender and medication that could alter sodium handling and BP. It is, however, possible that residual confounding remained even in multivariate analyses because it is hard, if not impossible, to adjust for (the severity of ) each confounder. Of the RTR, 41% used oral diuretics, which can acutely influence urinary sodium excretion. However, it is not likely that diuretics interfere in the association between sodium excretion and BP in RTR. Because these diuretics are chronic medication in RTR, who are at least 1 year after transplantation, sodium balance will be in steady state while on medication, with sodium excretion representing sodium intake.
Furthermore, our study population consisted predominantly of Caucasian people, making extrapolation of our results to other ethnicities difficult. Nevertheless, the large size of the study population involved, and the performance of the measurements in a standardized manner renders our finding of a positive association between sodium intake and BP reliable and robust. Additionally, secondary analyses on the association of UNaV with BP after exclusion of inadequately collected 24-h urine samples still showed a highly significant and even stronger positive association between sodium intake and BP, despite the reduction of sample size. Our current study adds to the rationale for dietary sodium intervention in RTR. The Multiple Risk Factor Intervention Trial showed that even small differences in population average BP relate importantly to CVD and all-cause mortality. It was estimated that a 4 mmHg reduction of SBP was associated with meaningful benefit: lower ischaemic heart disease and CVD death rates by 8-9% and lower all-cause mortality by 5.8% [34] . The study by Cook et al. [35] demonstrated that dietary sodium intervention can indeed improve longterm outcome. In agreement, it has been proposed that in RTR, even moderate BP lowering would already have favourable effects on CVD and mortality [4] . Moreover, recent post hoc analyses from the REIN [36] and the RENAAL/IDNT study [37] showed that a moderately lower sodium intake is associated with a substantially better long-term renal and cardiovascular outcome in non-diabetic and diabetic renal patients, respectively. To the best of our knowledge, no sodium intervention studies have been performed in RTR, which is remarkable, also considering the well-recognized beneficial effects of even a modest dietary sodium restriction to 90-100 mmol/day in patients with native kidney disease on BP and proteinuria [32, 38] .
The feasibility of persistent reduction of dietary sodium has been questioned, especially when it comes to compliance with strict recommendations in current guidelines for high-risk groups, including patients with CKD. For these groups, a sodium intake of no >1500 mg (∼70 mmol/day) is advocated [19] , based on the DASH-sodium trial, in which sodium intake was maintained at 65 mmol/day for 6 weeks [17] . Intervention studies from our own group showed that reduction to ∼100 mmol/day is feasible in a regular nephrology outpatient setting at least for the 6 week periods of the study [25, 38] . The recent hard end point data suggest that even a modest reduction in dietary sodium might already be highly beneficial in renal patients [36, 37] , which increases the feasibility of obtaining health benefits by dietary sodium restriction. Our current data support the relevance of such an approach in RTR.
Previous epidemiological studies in RTR did not detect an association between sodium intake and BP. However, these studies were either small, and therefore likely to be underpowered [9] [10] [11] , or there was a long time lag between assessment of sodium intake and BP, without BP measurements being performed in a standard way [12] . Taken together, these factors have likely hampered the power of those studies to detect an association between sodium intake and BP.
Our cross-sectional data make it reasonable to postulate that BP in RTR is sodium sensitive. This could be related to renal function and/or proteinuria as both renal function impairment and proteinuria are associated with increased sodium sensitivity of BP in native kidneys [38, 39] . Other factors could be the use of drugs interfering in the reninangiotensin-aldosterone system that generally render BP sodium sensitive [40] or the fact that many RTR are overweight, leading to increased sodium sensitivity of BP [41, 42] . Another factor that could underlie our findings is the use of calcineurin inhibitors by the majority of RTR, which has been shown to be related to hypertension [43] . Cyclosporine in particular activates the sympathetic nervous system, up-regulates endothelin, inhibits nitric oxide and enhances sodium retention, all of which cause potent vasoconstriction and systemic hypertension [44] [45] [46] .
Like in the general population, the unfavourable effects of sodium intake on BP in RTR are most likely the consequence of expansion of the extra cellular volume and the subsequent rise in cardiac output, a phenomenon that has already been shown to be related to high salt intake in healthy subjects [47, 48] . As a result of increased vascular stiffness in RTR, especially in those who underwent pretransplant dialysis [49] , the concomitant compensatory decrease in peripheral vascular resistance fails to occur and hypertension is more likely to develop as compared to healthy subjects.
Notwithstanding the above, the exact mechanisms of the interaction of sodium with BP in RTR are incompletely known, mainly because of a lack of sodium intervention studies in RTR.
Conclusions
Dietary sodium intake in RTR is below the level of healthy controls, but well above recommended targets. Our cross-sectional data show a positive association between sodium intake and BP in RTR. These data support the need for sodium intervention studies in RTR to improve BP and cardiovascular and renal risk in this population. Funding. The current manuscript was supported by Top Institute (TI) Food and Nutrition, which is a public/private partnership that generates vision on scientific breakthroughs in food and nutrition, resulting in the development of innovative products and technologies. Partners are major Dutch Food companies and research organizations. This does not alter the authors' adherence to all the policies of 'Nephrology, Dialysis and Transplantation' on sharing data and materials.
